News

Preannouncement - 2025 Joint Transnational Call for Proposals on Rare Disease Therapies

Published on
| 2 years ago
Programmes
  • Health

The European Partnership on Rare Diseases (ERDERA) has preannounced its first Joint Transnational Call for Proposals on Rare Disease Therapies. The content of the preannouncement may be subject to change.

The call will formally open on 10 December and will have a two-stage submission process with deadline for pre-proposals in February 2025 and full proposal deadline in July 2025.

Research Foundation Flanders (FWO) participates in this call. More information on available funding for researchers based in Flanders and on who can apply & how will become available on the FWO website after official opening of the call.

The primary objective of the call is to support interdisciplinary, transnational collaborations that leverage complementary expertise to develop new therapies for rare diseases. Research projects should focus on pre-clinical studies involving small molecules or biologicals. This could include the development of novel therapies, biomarkers for therapy efficiency, or replication of pre-clinical studies to validate findings.

More information is available on the ERDERA website.

Related news

myOverview

Sign up for personalised information

Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.

  • News in your domains
  • Event announcements
  • A personal dashboard
Sign up now

Only for stakeholders located in Flanders

Latest news

2049 articles available Browse all news
  • EIC

EIC Work Programme 2027 adopted

The 2027 work programme opens funding opportunities worth over €1.8 billion for strategic technologies and scaling up companies. The EIC work programme 2027 details the funding in six main schemes: EIC Pathfinder EIC Transition Advanced Innovation Challenges EIC Accelerator The EIC Strategic Technologies for Europe Platform (STEP) Scale Up EIC...

Read more
  • Defence
  • DIRS

Start2Def 2026 call open

The Start2Def 2026 selection process opened on 4 November 2026. Belgian startups and small SMEs can submit proof-of-concept ideas for one of two defence-related challenges.

Read more

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.